

Ghana Support for Meningitis A Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ghana					
2. Grant number: 1619-GHA-28a-X / 16-GHA-08j-Y					
3. Date of Decision Letter: 3 May 2016					
4. Date of the Partnership Framework Agreement: 11 July 2014					
5. Programme title: New Vaccine Support (NVS), Meningitis A Preventive Routine					
6. Vaccine type: Meningitis A					
7. Requested product presentation and formulation of vaccine: Meningococcal type A, 10 dose(s) per vial, LYOPHILISED					
8. Programme duration¹: 2016 - 2019					
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)					
	2016	2017	2018	2019	Total ²
Programme Budget (US\$)	US\$236,500	US\$807,000	US\$596,500	US\$514,500	US\$2,154,500
10. Vaccine introduction grant (in US\$): 914,500. Payable up to six months before vaccine introduction.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³					
Type of supplies to be purchased with Gavi funds in each year	2016	2017			
Number of Meningitis A vaccines doses	381,000	1,265,000			
Number of AD syringes	251,600	806,700			
Number of re-constitution syringes	42,000	139,200			
Number of safety boxes	3,250	10,425			
Annual Amounts (US\$)	US\$236,500	US\$807,000			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

13. Self-procurement: [Not applicable].

14. Co-financing obligations: Reference code: 1619-GHA-28a-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2016	2017	2018	2019
Number of vaccine doses	182,000	930,000	991,500	1,188,000
Number of AD syringes	120,000	592,600		
Number of re-constitution syringes	20,000	102,300		
Number of safety boxes	1,550	7,650		
Value of vaccine doses (US\$)	US\$99,331	US\$525,845		
Total co-financing payments (US\$) (including freight)	US\$113,000	US\$593,000	US\$647,500	US\$800,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Country shall provide the following clarifications to Gavi*: Not applicable

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Barry Greene
Managing Director, Finance & Operations
[3/May/2016]